Hemophilia is diagnosed by low Factor VII clotting activity, shown through blood tests (Konkle, 2011). The following are treatment options for the disease.
DDAVP, an oral prescription medication, is used by individuals with mild hemophilia to treat bleeding. The medication can double or triple factor VIII levels (U.S. National Library of Medicine, 2014). Donated Plasma some with hemophilia may use transfusions of donated plasma to replace their plasma with low factor VIII levels with normal plasma. However, this is sometimes difficult because of shortages of donated plasma. In addition, when this treatment was introduced, many individuals with hemophilia were affected by blood diseases within the new plasma (Stobbe, 2011). Factor Replacement Therapy In addition to plasma, factor XIII can be genetically engineered. Those with hemophilia may use this treatment once a day, or only when there is excessive bleeding. The genetically engineered factor XIII can keep the factor XIII in the body at normal levels for several hours (Seppa, 2001). |  |
